Vulnerabilities

Vulnerability · CVE-2026-31014

Dovestones Softwares AD Self Update <4.0.0.5 is vulnerable to Cross Site Request Forgery (CSRF).

Published Apr 21, 2026 · catalog updated Jun 17, 2026 · ad self update

Check if you run it

No confirmed exploitation is on record for CVE-2026-31014. EPSS is 0.14%. Act only if a listed version of ad self update is installed.

Gaps on this record

  • No vendor fix or required action is stored. Compare the linked advisory before you change production.
Severity
Medium6.3
Known exploitation
Not in CISA/VulnCheck KEV
EPSS
0.14%
Remediation
Version ranges on file
Affected products
cpe dovestones/ad self update · stated ad self update

Dovestones Softwares AD Self Update <4.0.0.5 is vulnerable to Cross Site Request Forgery (CSRF). The affected endpoint processes state-changing requests without requiring a CSRF token or equivalent protection. The endpoint accepts application/x-www-form-urlencoded requests, and an originally POST-based request can be converted to a GET request while still successfully updating user details. This allows an attacker to craft a malicious request that, when visited by an authenticated user, can modify user account information without their consent.

Are you affected?

Enter the version you run. The result uses only the ranges stored on this record.

The check returns affected, not affected, or incomplete. It does not guess a version that is missing from the record.

  • cpe dovestones/ad self updateversion unspecified
  • stated ad self update< 4.0.0

How to fix CVE-2026-31014

What to do

Three questions, each answered from this record only. Confirm the vendor advisory before you patch.

Should you patch?

No confirmed exploitation is on record for CVE-2026-31014. EPSS is 0.14%. Act only if a listed version of ad self update is installed.

Which versions are affected?

Compare what you have installed with ad self update < 4.0.0. Compare the installed version with the linked vendor advisory before you change production.

What should an analyst verify?

CWE-352: Cross-Site Request Forgery (CSRF). EPSS 0.14%. There is no CISA KEV listing. No Exploit-DB or Metasploit reference is linked. Use the source links for the original advisory.

Code

The project this record applies to. Exploit listings stay in References.

No public source repository is identified for this product.

Timeline

Detection, updates, and resolution for this record.

  1. Apr 21, 2026 · NIST NVD

    Detected

    Dovestones Softwares AD Self Update <4.0.0.5 is vulnerable to Cross Site Request Forgery (CSRF). The affected endpoint processes state-changing requests without requiring a CSRF token or equivalent protection. The endpoint accepts application/x-www-form-urlencoded requests, and an originally POST-based request can be converted to a GET request while still successfully updating user details. This a

  2. Jun 17, 2026 · NIST NVD

    Updated

    Dovestones Softwares AD Self Update <4.0.0.5 is vulnerable to Cross Site Request Forgery (CSRF). The affected endpoint processes state-changing requests without requiring a CSRF token or equivalent protection. The endpoint accepts application/x-www-form-urlencoded requests, and an originally POST-based request can be converted to a GET request while still successfully updating user details. This a

Sources

  • CVE.orgVulnerability recordCVE-2026-31014

    Official CVE identifier

    cve.org
  • FIRST EPSSExploitation probabilityCVE-2026-31014

    30-day exploitation probability 0.1%

    first.org
  • NIST NVDVulnerability recordCVE-2026-31014

    Dovestones Softwares AD Self Update <4.0.0.5 is vulnerable to Cross Site Request Forgery (CSRF). The affected endpoint processes state-changing requests without requiring a CSRF token or equivalent protection. The endpoint accepts application/x-www-form-urlencoded requests, and a

    nvd.nist.gov

References

Freshness

Last verified in this catalog Oct 18, 2026. Significant claims (KEV, EPSS, CVSS, affected ranges) come from the source rows above — open the original publisher for the authoritative advisory.